Table 2 Treatment-related adverse events (TRAEs)
|  | All grade n (%) | Grade 3–4 n (%) |
|---|---|---|
All TRAEs (n) | 20 (100.0) | 11 (55.0) |
 Platelet count decreased | 16 (80.0) | 9 (45.0) |
 White blood cell count decreased | 10 (50.0) | 0 (0.0) |
 Neutrophil count decreased | 10 (50.0) | 2 (10.0) |
 Hypothyroidism | 6 (30.0) | 0 (0.0) |
 Rash | 5 (25.0) | 0 (0.0) |
 Alanine aminotransferase increased | 5 (25.0) | 0 (0.0) |
 Aspartate aminotransferase increased | 4 (20.0) | 0 (0.0) |
 Anemia | 4 (20.0) | 0 (0.0) |
 Hepatic function abnormal | 3 (15.0) | 1 (5.0) |
 Vomiting | 3 (15.0) | 0 (0.0) |
 Nausea | 2 (10.0) | 0 (0.0) |
 Hyperchlorhydria | 2 (10.0) | 0 (0.0) |
 Thyroid function test abnormal | 2 (10.0) | 0 (0.0) |
 Hypokalemia | 2 (10.0) | 1 (5.0) |
 Hypesthesia | 2 (10.0) | 0 (0.0) |
 Pyrexia | 2 (10.0) | 0 (0.0) |
 Proteinuria | 2 (10.0) | 0 (0.0) |
 γ-glutamyl transferase increased | 1 (5.0) | 1 (5.0) |
 Diarrhea | 1 (5.0) | 1 (5.0) |
 Autoimmune colitis | 1 (5.0) | 1 (5.0) |
 Pneumonitis | 1 (5.0) | 1 (5.0) |